The use of early phototherapy in infants with ABO incompatibility is a commonly employed clinical practice by many pediatricians. Yaseen et al. 1 have provided a valuable addition to the literature regarding this practice. They found that while prophylactic phototherapy was associated with a significant decrease in total serum bilirubin within 48 hours, there was not sustained clinical benefit, and thus prophylactic phototherapy is not supported based on their data. Indeed, 68 percent of controls did not require phototherapy, so many infants treated in this manner would have received unnecessary intervention.
While the practice in their institution was to institute phototherapy at >95th percentile based on the Bhutani curve, 2 plotting their data from Table 2 against the current AAP recommendations for instituting phototherapy at 24 and 48 hours finds that few, if any, infants would have reached levels requiring phototherapy, although the guidelines state that it is an option to begin treatment at levels 2-3 mg/dl below the recommended levels. Further, do the authors have baseline hematocrit values and values at 24, 48, 72, or 96 hours for the infants studied to confirm a hemolytic process? What percentage of infants delivered by cesarean delivery in each group accounted for prolonged hospitalization, or were such infants routinely discharged at 48 hours unless they needed treatment for hyperbilirubinemia?
Congratulations to the authors for undertaking the study. It adds to our knowledge that prophylactic phototherapy in such infants is not indicated. The results, if accepted, will avoid the unnecessary separation of such infants from their mothers for phototherapy.
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